# US 2025/0082931 A1 · Treating Gastric Cancer Using TTFields Combined with XELOX, FOLFOX or the Individual Constituents Thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2025/0082931 A1 - Document ID: US20250082931A1 - Status: Published application - Kind: A1 - Application number: 18/609,450 - Filed: 2024-03-19 - Published: 2025-03-13 - Earliest claimed: 2019-02-22 - Assignees: Novocure GmbH - Applicants: Novocure GmbH - Inventors: Einav Zeevi; Karnit Gotlib; Rosa S. Shnaiderman; Moshe Giladi; Uri Weinberg - Web page: https://patentgrep.com/patent/US20250082931A1 ## CPC - A61K 9/0009: {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis} - A61N 1/36002: {Cancer treatment, e.g. tumour} - A61K 31/282: Platinum compounds - A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol - A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Methods of treating gastric cancer and reducing the viability of gastric cancer cells by administering folinic acid, fluorouracil, and oxaliplatin to a subject, and applying an alternating electric field to a target region of the subject are provided. In some instances, chemotherapy such as XELOX, FOLFOX and individual components thereof are administered to a subject followed by applying an alternating electric field to the subject. ## Claims ### Claim 1 A method of treating gastric cancer in a subject, the method comprising: administering oxaliplatin and capecitabine to the subject; and applying an alternating electric field to a target region of the subject, the alternating electric field having a frequency between 100 and 400 kHz. ### Claim 2 (depends on 1) The method of claim 1, wherein at least a portion of the applying is performed after the administering and before the oxaliplatin and capecitabine are eliminated from the subject's body. ### Claim 3 (depends on 1) The method of claim 1, wherein the applying has a duration of at least 72 hours. ### Claim 4 (depends on 1) The method of claim 1, wherein the frequency of the alternating electric field is between 120 and 180 KHz. ### Claim 5 (depends on 1) The method of claim 1, wherein the frequency of the alternating electric field is between 145 and 155 kHz. ### Claim 6 (depends on 1) The method of claim 1, wherein the oxaliplatin and capecitabine are administered at therapeutically effective doses, and wherein the alternating electric field has a field strength of at least 1 V/cm in at least a portion of the target region. ### Claim 7 (depends on 6) The method of claim 6, wherein the applying has a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 120 and 180 KHz. ### Claim 8 (depends on 6) The method of claim 6, wherein the applying has a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 145 and 155 kHz. ### Claim 9 A method of reducing viability of gastric cancer cells, the method comprising: administering oxaliplatin and capecitabine to the cancer cells; and applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz. ### Claim 10 (depends on 9) The method of claim 9, wherein at least a portion of the applying is performed simultaneously with at least a portion of the administering. ### Claim 11 (depends on 9) The method of claim 9, wherein the applying has a duration of at least 72 hours. ### Claim 12 (depends on 9) The method of claim 9, wherein the frequency of the alternating electric field is between 120 and 180 kHz. ### Claim 13 (depends on 9) The method of claim 9, wherein the frequency of the alternating electric field is between 145 and 155 kHz. ### Claim 14 (depends on 9) The method of claim 9, wherein each of the oxaliplatin and capecitabine is delivered to the cancer cells at a therapeutically effective concentration, and wherein the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells. ### Claim 15 (depends on 14) The method of claim 14, wherein the applying has a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 120 and 180 kHz. ### Claim 16 (depends on 14) The method of claim 14, wherein the applying has a duration of at least 72 hours and wherein the frequency of the alternating electric field is between 145 and 155 kHz.